Price
CHART BY
Frequently asked questions
What is Lantern Pharma's market capitalization?
The market capitalization of Lantern Pharma is $23.52M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Lantern Pharma?
Lantern Pharma's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$1.613. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Lantern Pharma's stock?
Currently, 3 analysts cover Lantern Pharma's stock, with a consensus target price of $18.00. Analyst ratings provide insights into the stock's expected performance.
What is the EBITDA for Lantern Pharma?
Lantern Pharma's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$15.45M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Lantern Pharma?
Lantern Pharma has a free cash flow of -$14.08M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Lantern Pharma have, and what sector and industry does it belong to?
Lantern Pharma employs approximately 16 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of Lantern Pharma's shares?
The free float of Lantern Pharma is 9.94M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $23.52M
- EPS (TTM)
- -$1.613
- Free Float
- 9.94M
- EBITDA (TTM)
- -$15.45M
- Free Cashflow (TTM)
- -$14.08M
Pricing
- 52W span
- $1.11$4.68
Analyst Ratings
The price target is $18.00 and the stock is covered by 3 analysts.
Buy
3
Hold
0
Sell
0
Information
Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. Its portfolio includes LP-100, LP-300, and LP-184. The company was founded by Arun K. Asaithambi, Gregory T. Tobin, and Peter L. Nara on November 7, 2013 and is headquartered in Dallas, TX.
- Employees
- 16
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- Primary Ticker
- LTRN
Fundamentals & EOD data from FactSet